Urogen Pharma (URGN)
(Delayed Data from NSDQ)
$13.42 USD
+0.07 (0.52%)
Updated Sep 10, 2024 04:00 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
Income Statements
Fiscal Year end for Urogen Pharma falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 83 | 64 | 48 | 12 | 0 |
Cost Of Goods | 9 | 8 | 5 | 1 | 0 |
Gross Profit | 73 | 57 | 43 | 11 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 139 | 136 | 135 | 138 | 110 |
Income After Depreciation & Amortization | -66 | -79 | -92 | -127 | -109 |
Non-Operating Income | -18 | -21 | -17 | 2 | 4 |
Interest Expense | 15 | 8 | 0 | 0 | 0 |
Pretax Income | -98 | -108 | -109 | -125 | -105 |
Income Taxes | 4 | 2 | 1 | 3 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -102 | -110 | -111 | -128 | -105 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -102 | -110 | -111 | -128 | -105 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -66 | -79 | -91 | -126 | -110 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 1 | 1 | 0 |
Income After Depreciation & Amortization | -66 | -79 | -92 | -127 | -109 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 28.83 | 22.81 | 22.35 | 21.78 | 20.53 |
Diluted EPS Before Non-Recurring Items | -3.55 | -4.79 | -4.96 | -5.90 | -5.12 |
Diluted Net EPS (GAAP) | -3.55 | -4.81 | -4.96 | -5.90 | -5.12 |
Fiscal Year end for Urogen Pharma falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 21.85 | 18.78 | 23.53 | 20.85 | 21.14 |
Cost Of Goods | 2.23 | 1.73 | 2.29 | 2.37 | 2.44 |
Gross Profit | 19.62 | 17.05 | 21.24 | 18.49 | 18.70 |
SG&A, R&D, and Dept/Amort Expenses | 45.46 | 42.79 | 35.85 | 31.99 | 34.07 |
Income After SG&A, R&D, and Dept/Amort Expenses | -25.84 | -25.74 | -14.61 | -13.50 | -15.37 |
Non-Operating Income | -4.07 | -4.05 | -3.97 | -4.57 | -4.94 |
Interest Expense | 3.46 | 2.45 | 3.59 | 3.82 | 3.76 |
Pretax Income | -33.37 | -32.23 | -22.16 | -21.89 | -24.08 |
Income Taxes | 0.04 | 0.05 | 3.85 | -0.01 | 0.05 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -33.40 | -32.29 | -26.02 | -21.88 | -24.14 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -33.40 | -32.29 | -26.02 | -21.88 | -24.14 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 36.82 | 33.38 | 36.15 | 32.30 | 23.46 |
Diluted EPS Before Non-Recurring Items | -0.91 | -0.97 | -0.72 | -0.68 | -1.03 |
Diluted Net EPS (GAAP) | -0.91 | -0.97 | -0.54 | -0.68 | -1.03 |